Acute and maintenance treatment of atopic dermatitis in children - Two comparative studies with fluticasone propionate (0.05%) cream

Journal of Dermatological Treatment

Volumn 14, Issue 3, 2003, Pages 141-148

  Kirkup, M E ^a   Birchall, N M ^b   Weinberg, E G ^c   Helm, K ^d   Kennedy, C T C ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b Auckland Dermatology   (New Zealand)

^c RED CROSS WAR MEMORIAL CHILDREN S HOSPITAL   (South Africa)

^d Bristol Royal Infirmary ^*

Author keywords

Atopic dermatitis; Children; Fluticasone propionate; Intermittent dosing; Long term management; Topical steroid

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREAM; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HUMAN; IMPETIGO; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN ATROPHY; UPPER RESPIRATORY TRACT INFECTION;

ACUTE DISEASE; ADMINISTRATION, TOPICAL; ADOLESCENT; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; MALE; OINTMENTS; TREATMENT OUTCOME;

EID: 0141920559     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630310013388     Document Type: Article

References (22)

1. Lamb SR, Rademaker M, Pharmacoeconomics of drug therapy for atopic dermatitis. Expert Opin Pharmacother (2002) 3: 249-55.
2. McNally NJ, Phillips DR, Williams HC, The problem of atopic eczema: aetiological clues from the environment and lifestyles. Soc Sci Med (1998) 46: 729-41.
3. Fennessy M, Coupland S, Popay J, Naysmith K, The epidemiology and experience of atopic eczema during childhood: a discussion paper on the implications of current knowledge for health care, public health policy and research. J Epidemiol Community Health (2000) 54: 581-9.
4. Daud LR, Garralda ME, David TJ, Psychosocial adjustment in pre-school children with atopic eczema. Arch Dis Child (1993) 69: 670-6.
5. Lawson V, Lewis Jones MS, Finlay AY et al. The family impact of childhood atopic dermatitis: the dermatitis Family Impact questionnaire. Br J Dermatol (1998) 138: 107-13.
6. Brazzini B, Pimpinelli N, New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol (2002) 31: 47-58.
7. Finlay AY, Principles of drug treatment in dermatology. Medicine (1997) 25: 7-10.
8. Charman CR, Morris AD, Williams HC, Topical corticosteroid phobia in patients with atopic eczema. Brit J of Dermatol (2000) 142: 931-6.
9. Hoare C, Li Wan Po A, Williams H, Systematic review of treatments of atopic eczema. Health Technol Assess (2000) 437: 25-30.
10. van der Meer JB, Glazenburg EJ, Mulder PGH et al, The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol (1999) 140: 1114-21.
11. Hanifin J, Gupta AK, Rajagopalan R, Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol (2002) 147: 1-10.
12. Berth-Jones J, Damstra R, Golsch S et al, Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ (2003) 326: 1367-1370.
13. Friedlander SF, Hebert A, Allen DB, Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol (2002) 46: 387-93.
14. Thomas KS, Armstrong S, Avery A et al, Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ (2002) 324: 768-71.
15. European Task Force on Atopic Dermatitis, Severity scoring of atopic dermatitis: the SCORAD index. Dermatology (1993) 186: 23-31.
16. Hanifin JM, Thurston M, Omoto M et al, The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol (2001) 10: 11-18.
17. Hanifin JM, Tofte SJ, Update on therapy of atopic dermatitis. JACI (1999) 104: S123-125.
18. Juhlin L, Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-17- butyrate cream, 0.1%, in the treatment of eczema. Cutis (1996) 57: 43-8.
19. Spencer CM, Wiseman LR, Topical fluticasone propionate. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Biodrugs (1997) 4: 318-34.
20. Wolkerstorfer A, Strobos MA, Glazenburg EJ et al, Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice in children with atopic dermatitis. J Am Acad Dermatol (1998) 39: 226-31.
21. Dykes P, Marks R, Hill S et al, The kinetics of skin thinning induced by topical fluticasone propionate 0.05% cream in volunteer subjects. Clin & Exp Dermatol (1996) 21: 185-9.
22. Westerhof W, Nieuweboer-Krobotova L, Mulder P et al, Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol (1999) 135: 1061-66.